Friday, September 23, 2011
8:00 – 9:00 a.m.

LSU Health Sciences Center – Shreveport
Lecture Hall, Room 3-322

“Legal & Ethical Issues in Neurology”

Andrew A. Marino, PhD, JD
Professor of Neurology
LSU Health Sciences Center – Shreveport

Learning Objectives:
At the completion of this regularly scheduled activity, participants should be able to:
- Discuss the basic constraints on neurologic practice
- Explicate the constraints by means of specific examples

Disclosure: Dr. Marino has no significant conflict of interest.

The Louisiana State University Health Science Center-Shreveport, School of Medicine, is accredited by the ACCME to provide continuing medical education for physicians.

The Louisiana State University Health Science Center-Shreveport, School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

No commercial support was provided for this program.
Legal/Ethical Issues in Neurology
Andrew A. Marino, Ph.D., J.D.
Department of Neurology

Summary

- Legal/ethical constraints on neurologic practice
- AAN perspective
- Three specific issues
- Inter-relationship of constraints

I'll discuss the general classes of constraints, the perspective of the American Academy of Neurology, and three specific issues. I'll conclude that legal constraints have the most immediate and practical impact on neurologic practice.

Constraints on Neurologic Practice

Constraints may arise from considerations of professional responsibilities, ethical or moral considerations, or from the demands and requirements of applicable laws. Some issues can be classified and discussed in the context of one or perhaps two of the constraints, but probably the most complex issues faced in practice involve issues that contain elements of all three constraints.
A practicing neurologist is expected to act in a professional manner. We can get an idea of what that means by examining what ethical dimensions the Academy considers necessary for teaching neurologists-in-training.

TABLE OF CONTENTS

1. Introduction
2. Truth-telling and Disclosure
3. Huntington’s Disease—Presymptomatic Genetic Testing
4. Care of the HIV-infected Patient in a Managed Care Environment
5. Narcotic Treatment of Chronic Nonmalignant Pain
6. Persistent Vegetative State
7. Dementia
8. Brain Death and Stopping Treatment
9. Physician-assisted dying
10. A Small Sick Newborn
11. Uncooperative Parents
12. Clinical Trials
13. Mistakes
14. Gifts from Industry
15. Professional Misconduct of a Sexual Nature

These are the topics in the recommended curriculum for residents. With the exception of neuroenhancers, which I’ll discuss shortly, no other major topics have arisen in the last 10 years.
Pick Issues to Emphasize Legal Aspect

All of the specific issues that arise are three-dimensional in the sense that, in varying proportions, they involve all three general constraints. I adopted a legal perspective and ranked some important issues along that axis. In this perspective, and speaking qualitatively, I ranked the legal proportion of the constraint for the indicated specific issues. For discussion purposes I chose issues at the low and high end of the legal scale, and the issue of neuroenhancers which I think is somewhere in the middle but has the potential to move up the scale.

First Issue: The Malpractice Iceberg

- Small fraction of negligence cases → lawsuit.
- Some lawsuits even in absence of negligent care.


Positive law has its greatest impact in the issue of malpractice. There are two salient points. First, the number of lawsuits represents only a tiny minority of the possible lawsuits, that is, of cases involving harm to patients brought about by culpable errors by the neurologist. Physicians are human beings, human beings make errors, and errors sometimes result in harm for patients. The number and impact of these errors can be minimized, but not eliminated. Second, some malpractice cases do not involve physician errors. In other words, there are cases where lawsuits could have been brought but weren’t, and cases where they were brought but should not have been. Consequently, malpractice claims are uncorrelated with quality of care.
Longitudinal Analysis of Neurologic-Patient Malpractice Claims

- Harvard
- Closed claims 1986–2004
- ≥1 neurologist (resident or staff)
- 42 claims


When a lawsuit is brought against a neurologist, what are the typical reasons, and what are the conditions that might generalize and hence merit prospective consideration? I think we can find some useful answers from a study done at the Harvard teaching institutions. The study evaluated all claims that involved a neurologist during a 15-year period, and 42 such claims were identified and analyzed.

Evaluation of 24 Neurologic Claims

- Basis of claim: Failure to diagnose: 63%
- Supervision Issue: 25%

In the judgment of the authors 24 claims were malpractice (physician errors that resulted in patient harm). Although the percentages vary widely from study to study depending on the criterion adopted, about 50% is probably a reasonable average for the number of malpractice suits that actually involved physician malpractice. Only a small percentage of the cases in this study originated in the emergency department. Among the possible explanations is the law’s reluctance to recognize liability when a physician is functioning under emergency situations. The Good Samaritan laws, which exist in essentially all the states, exemplify this attitude. Seventeen of the 24 cases of actual malpractice involved some form of miscommunication between the neurologist and either another physician, or the patient. The take-home message is: be especially on guard in a non-ED setting during your first encounter with the patient, and empathize.
The Academy published a Code of Professional Conduct that explicitly treats eight general areas, and it developed a disciplinary process for handling cases of alleged violation of the Code.

The process is triggered when the Academy receives a written complaint concerning the conduct of a member and involves the indicated procedural steps leading to either dismissal of the complaint or a disciplinary action.
Complaints Received

<table>
<thead>
<tr>
<th>Year</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>3</td>
</tr>
<tr>
<td>2005</td>
<td>5</td>
</tr>
<tr>
<td>2006</td>
<td>12</td>
</tr>
<tr>
<td>2007</td>
<td>6</td>
</tr>
<tr>
<td>2008</td>
<td>16</td>
</tr>
<tr>
<td>2009</td>
<td>16</td>
</tr>
</tbody>
</table>

- 3 Resignations
- 6 Disciplinary Actions


The Academy’s disciplinary process has rarely been invoked. Considering that there are about 10,000 members, the data shows that the disciplinary rate is about $10^{-6}$% per year. It’s clear, therefore, that the Code is not coercive, like positive law, but rather aspirational, like an ethical principle.

---

Third Issue: Neuroenhancers for Improving Cognitive Function in Clinically Normal Subjects

The issue of neuroenhancers has a legal impact on neurologists that is somewhere between the Academy’s Code of Conduct and the civil law’s tort of negligence.
The use of neuroenhancers raises fundamental questions regarding what it means to be a physician. Historically a physician was conceived of as an individual who diagnosed and treated diseases. But people who take neuroenhancers are clinically normal but take drugs for the purpose of achieving greater-than-normal performance. The fundamental issue regarding whether neurologists ought to prescribe drugs for the purpose of improving normal behavior was discussed in an earlier Grand Rounds. I am revisiting the question from the legal perspective, asking what the liability might be for a neurologist who prescribes neuroenhancers to a patient who requests them.

The question of the professional legitimization of neuroenhancers has arisen only recently.
Influential Articles in *Nature*

**Neurocognitive enhancement: what Can we do and what should we do? (2004)**

“The enhancement of normal neurocognitive function by pharmacological means is already a fact of life.”

“The question is not whether we need policies, but rather what kind of policies we need to govern neurocognitive enhancement.”

**Towards responsible use of cognitive-enhancing drugs by the healthy (2008)**

“We should welcome new methods of improving our brain function.”

“Many kinds of employee may benefit from enhancement.”

“Technological fixes do not offer a path to moral absolution, but to technical resolution.”

Several influential articles advocating the use of neuroenhancers significantly increased pressure on neurologists to prescribe the drugs. It is noteworthy that the authors of these articles were famous basic scientists and authors of well-known textbooks in neuroscience, and representatives of drug companies. None of the authors were neurologists.

**Putative Brain Boosters**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Medical Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate (Ritalin®, Concerta®)</td>
<td>ADHD, Narcolepsy</td>
</tr>
<tr>
<td>Amphetamines (Adderall®)</td>
<td>ADHD, Narcolepsy</td>
</tr>
<tr>
<td>Modafinil (Provigil®)</td>
<td>Excessive daytime sleepiness due to obstructive sleep apnea</td>
</tr>
<tr>
<td>Donepezil (Aricept®)</td>
<td>Cognitive deficits of Alzheimer’s</td>
</tr>
</tbody>
</table>

This is a list of some representative drugs being used as neuroenhancers. Each of these drugs was approved for use in treating a specific neurological disorder. None were approved by the US FDA as brain boosters, nor have any been studied using randomized controlled studies.
It’s not clear why neurology rather than psychiatry has become the focus of considerations involving neuroenhancers. Various disorders are studied to different degrees in both specialties, but thus far only the Academy of Neurology has formally considered the impact of enhancers on neurologic practice.

Prospects in the Pipeline for Neuroenhancers

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Developers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicotinic acetylcholine receptor activators</td>
<td>Abbot, CoMentis, EnVivo, Targacept/AstraZeneca</td>
</tr>
<tr>
<td>Ampakines</td>
<td>Cortex Pharmaceuticals; Eli Lilly, GlaxoSmithKline/Neurosearch, Organon, Pfizer, Servier</td>
</tr>
<tr>
<td>Phosphodiesterase inhibitors</td>
<td>Helicon Therapeutics, Hoffmann-La Roche, Merck</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>GlaxoSmithKline, Johnson &amp; Johnson, Medivation/Pfizer</td>
</tr>
</tbody>
</table>

The issue of neuroenhancers seems likely to continue and increase in its public profile. Many drug companies are developing different classes of potential neuroenhancers.
Not all potential neuroenhancers are drugs. Transcranial electrical stimulation has been suggested as a possible neuroenhancer. The technique is FDA approved for the treatment of anxiety, depression, and insomnia. The initial approvals were given before there was any meaningful device legislation, and all similar devices since then have been grandfathered under the current law.

Transcranial Magnetic Stimulation

Transcranial magnetic stimulation which is a fundamentally different electrical stimulation technique has also been suggested as a modality for producing neuroenhancement.
The Academy considered the issue of neuroenhancements and adopted a relatively neutral position, which is probably appropriate, given the extent of its authority and its role in neurologic practice. The Academy committee reached the significant if somewhat understated conclusion that liability risks associated with prescribing neuroenhancers are uncertain.

**Neuroenhancers and the Law**

- No cases MD’s prosecuted/sued in relation to neuroenhancement
- Discussion based on potential legal liability

There are no actual cases involving neurologists being sued in connection with prescribing neuroenhancers to clinically normal patients, but I can discuss the potential legal liability by considering how the law would apply in a hypothetical situation.
Liability Considerations Regarding Prescribing Neuroenhancers

Hypothetical Case

University student tells her neurologist she’s having trouble staying focused and retaining information. Her roommate had the same problems and got much better when she used her brother’s Ritalin. Mindful of the Academy Committee advice, the neurologist prescribed the drug, which the student took through the school year when facing exams and deadlines for papers. She began experiencing serious psychotic symptoms and had to leave school. She sued the neurologist. What are the legal issues?

Consider this hypothetical case.

Legal Elements in the Case

- Doctor/patient relationship
- Neurologic standard of care
- Violation of standard
- Harm
- Neurologist defenses
- Patient contributory negligence

These are the legal elements in the case. I want to focus my analysis on the elements where the evidence would be most contentious, namely the elements involving the standard of care.

Does Prescribing Ritalin for Cognitive Enhancement Violate the Standard of Care?

- Unreasonable risk of harm
  - Probability of harm $<_{\text{High}}^{\text{Low}}$?
  - Cost of avoiding the risk $<_{\text{Low}}^{\text{High}}$?
  - Social utility of prescription $<_{\text{High}}^{\text{Low}}$?
  - Accepted by a ≥ respected minority of neurologists

As with any negligence action the key issue involves whether there was an unreasonable risk of harm. I've listed several considerations regarding which evidence might be adduced to argue that there was or was not an unreasonable risk.
Violation of Standard: Act of Prescribing

- **Warning**: Ritalin should not be used for prevention or treatment of normal fatigue states.
- No peer-reviewed-publication evidence that neurologists prescribe Ritalin for neuroenhancement
- Don’t know the probability for harm
- Possible harms are serious
- Efficacy is unknown
- Social utility is dubious

One argument the plaintiff might make is that the act of prescribing Ritalin was a violation of the applicable standard of care. The plaintiff could then present several lines of evidence which, individually and collectively, could persuade a jury that the standard of care was breached. For example, the Ritalin package label specifically warns against using Ritalin in the manner in which it was prescribed for the plaintiff. There are no peer-reviewed publications supporting the prescription of Ritalin for neuroenhancement. The probability that it might result in harm when prescribed to normal subjects is unknown and unstudied. From studies of the clinical use of Ritalin for ADHD, the possible harms that might result are known, and are recognized as serious. It can be seen that there is considerable evidence that could persuade a jury that prescribing Ritalin for normal subjects is a violation of the standard of care.

Violation of Standard: No Warning or Informed Consent

- Family history of Tourette’s Syndrome?
- Any contra-indicated conditions (long list)?
- Patient warnings given (long list)?
- Lack of evidence of efficacy disclosed?
- Informed consent process not billable (not medically necessary services)

Even if prescribing Ritalin wasn’t a violation, a failure to obtain informed consent could be pleaded and proved by the plaintiff as a violation of the standard of care. The plaintiff would present evidence indicating that she was never explicitly warned about the long list of potential side-effects associated with use of Ritalin. The failure to obtain informed consent, by itself, could constitute a violation of the standard of care.
Given the available evidence concerning the efficacy of neuroenhancers and their risks, and considering basic principles and rules of evidence regarding malpractice, prescribing neuroenhancers to a normal patient for the purpose of enhancing normal behavior is probably among the least wise things a neurologist could do.

Conclusion

The practicing neurologist is subject to ethical and professional constraints, but probably the legal constraints are more immediate, and more likely to have an impact on practice on a day-in and day-out basis. Consequently it is prudent to think about them on a daily basis.